Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment

Oncology

Top 5 Cancers Creating Major Challenge To The G...

Over the past few decades Cancer has emerged as a major public health concern worldwide. Cancer is the second leading cause of deaths that takes place worldwide. Every sixth death is due to cancer,...

Jul 01, 2020

pharma-news
Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab’s result; Orca raises $192M

Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and Longwood Fund and has an aim to create antibodies for cancer and fibrosis treatment. IL-11, a cytokine that plays a role in both disease are...

Find More
pharma-news
Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL

Alnylam Pharmaceuticals has released the Phase III results of the clinical trial ILLUMINATE-A evaluating lumasiran for Primary Hyperoxaluria Type 1 Primary Hyperoxaluria Type 1 (PH1) is a rare disorder that affects kidneys due to an excess buildup of oxalate, which in normal cases is filtered through the kidneys...

Find More
Uveitis-market
One of the leading causes of blindness, and a sight-threatening disease, Uveitis, now has novel treatment approaches in its pipeline

Uveitis is an ocular inflammation of the uveal tract, the middle layer of the eyeball. The uveal layer is responsible for nourishing the eye, and if damaged, leads to progressive and irreversible damage. Uveitis generally starts from the damage in the uveal layer; however, the disease is not at all confined to the ...

Find More

More Views & Analysis

Precision-Medicine
Precision Medicine: An emerging approach to conventional treatment

As per WHO, “Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer”. The patients whose lives are afflicted with similar types of cancers have long been administered a similar type of treatment regimen b...

Find More

pharma-news
Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost

Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 billion on Peloton Therapeutics, and the deal is promising.  The drug limited tumour growth in 43% and shrank tumors in 28% of patients...

Find More

Ovarian Cancer Market
Altering the course of Ovarian cancer with emerging therapies in the horizon

Many players such as Immunogen, On Target Laboratories, ImmunoVaccine Technologies, OncoQuest, Precigen, and some others are involved in developing therapies to accelerate the Ovarian Cancer Market. Cancer, coronary heart disease, and stroke are the leading contributors of the mortality worldwide, estimated ...

Find More

Non-Small Cell Lung Cancer Market Insights
Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses

Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...

Find More

Neoantigen based Personalized Cancer Therapeutic Vaccines Market
Changing the Paradigm of Cancer: Neoantigen based Personalized Cancer Therapeutic Vaccines

Neoantigen based Personalized Cancer Therapeutic Vaccines Market is advancing owing to bioinformatics-technological advancements, improved diagnosis, and a strong pipeline. Cancer therapeutic vaccines, unlike prophylactic vaccines, form a therapeutic option for the late-stage cancer patients in which the body’...

Find More

pharma news
Immunomedics Halts Sacituzumab govitecan trial; GSK-Vir Biotech collaboration; INO-4800 DNA COVID-19 Vaccine; Pfizer Commits $ 40M for COVID-19

Immunomedics discontinues its trial early – hopes for accelerated approval of Sacituzumab govitecan for mTNBC Immunomedics- a New Jersey-based pharmaceutical company has announced to freeze its Phase III confirmatory ASCENT clinical trial of sacituzumab govitecan aimed at treating metastatic triple-negative brea...

Find More

The convergence of technologies and the increasing integration of medical devices to computer networ.....

Find More

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that results in systemic inflamma.....

Find More

Methicillin-resistant Staphylococcus aureus (MRSA) infection is caused by bacteria that have become .....

Find More

Virtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with t.....

Find More

Doctors and scientists have recognized that traditional, complementary and alternative therapies hav.....

Find More

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally .....

Find More